Cargando…
Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199665/ https://www.ncbi.nlm.nih.gov/pubmed/37210537 http://dx.doi.org/10.1186/s13020-023-00751-7 |
_version_ | 1785044979686572032 |
---|---|
author | Yu, Yi-xuan Wang, Shuo Liu, Zhe-ning Zhang, Xu Hu, Zi-xin Dong, Hui-jing Lu, Xing-yu Zheng, Jia-bin Cui, Hui-juan |
author_facet | Yu, Yi-xuan Wang, Shuo Liu, Zhe-ning Zhang, Xu Hu, Zi-xin Dong, Hui-jing Lu, Xing-yu Zheng, Jia-bin Cui, Hui-juan |
author_sort | Yu, Yi-xuan |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with Western medicine in the field of oncology treatment. TCM with ICIs works by regulating the tumor microenvironment and modulating gut microbiota. Through multiple targets and multiple means, TCM enhances the efficacy of ICIs, reverses resistance, and effectively prevents and treats ICI-related adverse events based on basic and clinical studies. However, there have been few conclusions on this topic. This review summarizes the development of TCM in cancer treatment, the mechanisms underlying the combination of TCM and ICIs, existing studies, ongoing trials, and prospects for future development. |
format | Online Article Text |
id | pubmed-10199665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101996652023-05-22 Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions Yu, Yi-xuan Wang, Shuo Liu, Zhe-ning Zhang, Xu Hu, Zi-xin Dong, Hui-jing Lu, Xing-yu Zheng, Jia-bin Cui, Hui-juan Chin Med Review Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with Western medicine in the field of oncology treatment. TCM with ICIs works by regulating the tumor microenvironment and modulating gut microbiota. Through multiple targets and multiple means, TCM enhances the efficacy of ICIs, reverses resistance, and effectively prevents and treats ICI-related adverse events based on basic and clinical studies. However, there have been few conclusions on this topic. This review summarizes the development of TCM in cancer treatment, the mechanisms underlying the combination of TCM and ICIs, existing studies, ongoing trials, and prospects for future development. BioMed Central 2023-05-20 /pmc/articles/PMC10199665/ /pubmed/37210537 http://dx.doi.org/10.1186/s13020-023-00751-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Yu, Yi-xuan Wang, Shuo Liu, Zhe-ning Zhang, Xu Hu, Zi-xin Dong, Hui-jing Lu, Xing-yu Zheng, Jia-bin Cui, Hui-juan Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
title | Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
title_full | Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
title_fullStr | Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
title_full_unstemmed | Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
title_short | Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
title_sort | traditional chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199665/ https://www.ncbi.nlm.nih.gov/pubmed/37210537 http://dx.doi.org/10.1186/s13020-023-00751-7 |
work_keys_str_mv | AT yuyixuan traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT wangshuo traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT liuzhening traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT zhangxu traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT huzixin traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT donghuijing traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT luxingyu traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT zhengjiabin traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections AT cuihuijuan traditionalchinesemedicineintheeraofimmunecheckpointinhibitortheorydevelopmentandfuturedirections |